Abstract
Background: Porphyromonas gingivalis, a keystone pathogen and one of the primary pathogens responsible for periodontitis, leads to a chronic inflammatory condition that destroys the periodontal tissues and ultimately results in tooth loss. While conventional non-surgical therapy combined with antibiotics and local drug delivery systems are commonly used to treat periodontitis, certain medicinal herbs have also demonstrated efficacy in its prevention. Cissus quadrangularis L. (CQ), a perennial plant from the Vitaceae family, is widely recognized and used as a medicinal herb in many tropical countries, predominantly in India, Sri Lanka, Thailand, Java, West Africa, and the Philippines.
Aim: The aim of the study was to determine the antibacterial activity of CQ against the periodontal keystone pathogen P. gingivalis.
Method: Aqueous and ethanolic extracts of CQ were prepared using a Soxhlet extractor. The antibacterial effectiveness of these extracts against the periodontal pathogen P. gingivalis was evaluated at different concentrations, and the minimal inhibitory concentration (MIC) was determined using broth microdilution.
Results: The ethanolic extract of CQ mixed with 10% dimethyl sulfoxide (DMSO) showed higher inhibition compared to the aqueous extract of CQ against P. gingivalis.
Conclusion: Our study revealed the potent inhibitory effects of CQ against P. gingivalis. Both aqueous and ethanolic extracts displayed MIC values of 500 µg/mL. Notably, the ethanolic extract of CQ, dissolved in 10% DMSO, demonstrated superior efficacy with a lower IC50 value of 194.36 µg/mL. These findings indicate promising potential for CQ in the management of periodontal disease.
Keywords: porphyromonas gingivalis, minimum inhibitory concentration, ethanolic extract, cissus quadrangularis, antibacterial activity
Introduction
The keystone pathogen Porphyromonas gingivalis is prominently implicated in periodontitis, a chronic inflammatory condition that results in tooth loss and the damage of gingiva, alveolar bone, and periodontal ligaments [1]. Among the myriad bacterial species inhabiting the oral cavity, this specific gram-negative rod bacterium is non-motile and requires anaerobic conditions to survive. After 3-5 days of incubation, it forms black-pigmented colonies on supplemented blood agar plates [2,3]. By interacting with commensal Streptococci, P. gingivalis causes secondary infections in periodontal tissues [4]. Its capacity to elude host immune responses and disseminate via cell-to-cell interactions or hematogenous routes sustains persistent irritation in the peripheral regions [5].
Presently, periodontitis management involves systemic and localized antibiotic therapy, sometimes coupled with surgical interventions for addressing deep-pocket irritations [6]. Anaerobic bacteria, especially P. gingivalis, are the target of antibiotics. A range of antibiotics such as metronidazole, amoxicillin, amoxicillin/clavulanic acid, clindamycin, tetracycline, and fluoroquinolones are utilized alongside mechanical debridement [7,8].
Failure to perform debridement can lead to antibiotics being unable to penetrate biofilm, resulting in significantly higher minimal inhibitory concentrations (MIC) [9]. Moreover, P. gingivalis strains exhibit considerable resistance rates, reaching up to 21.56% for metronidazole, 25.49% for amoxicillin, and 23.52% for clindamycin [10]. Notable resistance is also observed for penicillin, erythromycin, azithromycin, and tetracycline [11].
As antibiotic resistance escalates, the imperative for new antimicrobials intensifies, yet the rate of new antibiotic discoveries has declined [12]. Medicinal plants offer another avenue for combating P. gingivalis infections. Not only do plant species represent a diverse reservoir of antibacterial compounds [13], but ethnobotanical knowledge can guide the selection of plant extracts for discovering novel antibacterials [14]. Extensive ethnobotanical documentation exists regarding plant usage for oral health, yet further research is assured to establish the pharmacological efficacy of these ethnomedicinal practices against dental pathogens.
Cissus quadrangularis (CQ), also known as Veldt Grape or Devil's Backbone, belongs to the Vitaceae family. It is recognized by various names, including Asthisamharaka, Hadjod, Pirandai, Mangara Valli, and Vitis quadrangularis [15-19]. Utilized in Ayurvedic and Siddha medicine traditions, it offers a range of therapeutic benefits, including antimicrobial, antiulcer, antioxidative, anti-osteoporotic, gastroprotective, cholinergic, antihyperglycemic, and cardiovascular properties [19]. This cactus-like plant is characterized by jointed climbers with simple tendrils and leaves that are either simple or lobed, cordate, serrate, or dentate. Its small, greenish-white, bisexual, and tetramerous flowers complement its versatile medicinal properties (Figure 1). This plant possesses the capability to mend bones, earning it the epithet "bone setter" [20].
It was discovered to exhibit anti-osteoporotic, antioxidant, antimicrobial, anticonvulsant, sedative, neuropharmacological, central nervous system (CNS) activity, anthelmintic, antidiabetic, antistress, anticancerous potential, and antinociceptive properties [18,21].
Previous research has revealed varying degrees of antibacterial efficacy against different microorganisms [16], yet scant literature has examined its antibacterial activity specifically against P. gingivalis. Therefore, this study aimed to assess the antibacterial potential of CQ against this significant periodontal pathogen.
Materials and methods
Collection of sample
Commercially available CQ powder (Bixa Botanicals, Dhar, India), also known as Hadjod stem powder, was used.
Preparation of ethanolic extract of CQ (Soxhlet extraction method)
Ethanolic extract of CQ was prepared using a Soxhlet extractor (Figure 1). Among conventional methods, Soxhlet was the most powerful method and had the most extraction yields [22]. The solvent (250 mL ethanol) was filled in the percolator. Finely ground powder of CQ (25 g) was packed using Whatman filter paper and placed inside the thimble. The solvent (ethanol) was heated by adjusting the temperature of the mantle to 50°C to reflux. The solvent vapor that travels up the distillation arm was cooled by the water that circulates in the condenser. The active compounds of CQ were extracted in ethanol. The cycle was repeated thrice to enable the complete extraction of the bioactive compounds present in CQ. After extraction, the solvent was evaporated to yield the extracted compounds (Figure 2). The ethanolic extract of CQwas dissolved in 10% dimethyl sulfoxide (DMSO) at a concentration of 25 mg/mL. Similarly, the aqueous extract was also obtained using the Soxhlet extraction method.
Preparation of bacterial suspension
From the maintained frozen stock cultures of P. gingivalis (ATCC No-33277), a small quantity of cells was recovered and subcultured. Brain heart infusion (BHI) broth was used as the culture medium to support the growth of bacteria. This culture was transferred into tubes containing 2 mL of the BHI medium to obtain a culture suspension of P. gingivalis. The selected test bacterial strain was adjusted to 0.5 McFarland turbidity standards.
MIC by broth dilution method
The MIC was calculated using the broth microdilution method with a 96-well polystyrene flat bottom plate. From columns 2 to 8, 50 μL of Mueller Hinton broth (MHB) was added to the microtiter plate. Then, 100 μL of the sample was added to the first well and serially diluted to the eighth well (1000 μg/mL to 7.8 μg/mL) (rows A and D: aqueous extract of CQ; rows B and E: ethanolic extract of CQdissolved in 10% DMSO). The 10th and 11th wells served as sterility and negative controls. Then, 50 μL of the P. gingivalis (ATCC® 33277) suspensions (0.5 McFarland) was added to all columns except the sterility column (Figure 3). The 96-well plate was read at 600 nm after being incubated for 24 hours at 37 °C. MIC was determined by comparing the growth rate of the tested bacterial strain with the negative controls. The lowest extract concentration that inhibited bacterial growth was noted as MIC.
Results
The MIC data reveal intriguing insights into the inhibitory potential of Sample 1 (an aqueous extract of CQ) and Sample 2 (an ethanolic extract of CQ dissolved in 10% DMSO) at varying concentrations. The concentrations tested ranged from 1000 µg/mL to 7.8125 µg/mL. The MIC, representing the minimum concentration at which microbiological development is prevented, is a critical parameter in assessing the effectiveness of antimicrobial agents. The MIC of Samples 1 and 2 was determined to be 500 µg/mL, with inhibitory percentages of 70.19% and 77.57%, respectively (Table 1 and Figure 5). As per standard protocol, the IC50 of Samples 1 and 2 was determined to be 240.46 µg/mL and 194.36 µg/mL, respectively. The inhibitory effect of the ethanolic extract of CQ dissolved in 10% DMSO was better than that of the aqueous extract of CQ. The broth microdilution method illustrated in Figure 3 provides a visual representation of the antimicrobial activity of the samples, highlighting their ability to inhibit bacterial growth at varying concentrations. Furthermore, Figure 4 depicts the activity of the samples compared to the control in terms of optical density (600 nm), reaffirming their effectiveness in suppressing bacterial proliferation.
Table 1. Inhibitory Percentage and IC50.
Concentration (µg/mL) | Sample 1 | Sample 1 - IC50 | Sample 2 | Sample 2 - IC50 |
1000 | 83.56 | 240.46 µg/mL | 87.33 | 194.36 µg/mL |
500 | 70.19 | 77.57 | ||
250 | 53.37 | 59.75 | ||
125 | 39.09 | 41.47 | ||
62.5 | 26.34 | 29.26 | ||
31.25 | 23.89 | 25.34 | ||
15.63 | 20.74 | 24.04 | ||
7.81 | 7.07 | 18.89 |
Discussion
Gingivitis and periodontitis are prevalent periodontal disorders that impact a substantial proportion of the worldwide population. These chronic inflammatory diseases are predominantly caused by an excess of certain anaerobic bacterial species in dental plaque. This is usually treated with mechanical methods (scaling and root planing, or SRP), but these methods are not always successful because of pathogens that can invade tissue. Systemic and local antibiotics may be beneficial when used in conjunction with mechanical treatment. However, widespread antibiotic use can lead to antibiotic resistance. As a result, research over the past ten years has concentrated on medicinal plants with anti-inflammatory and antibacterial properties to treat these ailments.
The foundations of traditional medicinal systems have historically been plants [23]. Plant extracts, in particular, have emerged as promising natural antibacterial agents with diverse therapeutic applications for combating pathogenic bacteria. CQ, for instance, contains a plethora of beneficial compounds such as carotene, phytosterol, terpenoids, β-sitosterol, δ-amyrin, δ-amyrone, calcium, flavonoids like quercetin, vitamin C, and stilbene derivatives such as resveratrol, piceatannol, pallidol, perthenocissin, and phytosterols [15].
The aqueous and ethanolic extracts of CQ were selected for the current investigation in order to assess their antibacterial activity against P. gingivalis, the keystone periodontal pathogen. The results of our study shed light on the inhibitory potential of two different samples of CQ aqueous and ethanolic extracts against P. gingivalis, a prominent periodontal pathogen. The MIC data reveal the inhibitory potential of Sample 1 (an aqueous extract of CQ) and Sample 2 (an ethanolic extract of CQ dissolved in 10% DMSO) at varying concentrations. The concentrations tested ranged from 1000 µg/mL to 7.8125 µg/mL. The MIC of Samples 1 and 2 was determined to be 500 µg/mL. Additionally, the inhibitory percentages of Sample 1 and Sample 2 were found to be 70.19% and 77.57%, respectively.
The determination of the half-maximal inhibitory concentration (IC50) further elucidated the potency of the samples, with Sample 2 exhibiting a lower IC50 value (194.36 µg/mL) compared to Sample 1 (240.46 µg/mL). These findings indicate that the ethanolic extract of CQ formulated with 10% DMSO possessed enhanced antibacterial activity against P. gingivalis compared to the aqueous extract (Sample 1). The results were consistent with the findings of Nadhini et al., who reported that the ethanolic extract of CQ exhibited the highest level of antibacterial activity against clinical pathogens [24]. They stated that the ethanolic extract was most frequently used and showed a reasonable antibacterial effect.
Multiple clinical investigations have indicated that administering CQ within a range of 1.2-10 g/day for durations spanning 4-12 weeks led to an acceleration in bone fracture healing, without encountering severe adverse events (AEs). These clinical observations find reinforcement in various in vivo and in vitro studies focusing on bone-related outcomes. Such collective evidence underscores the potential of CQ as an alternative approach to mitigating bone loss [25,26].
The traditional medicinal practice of Ayurveda has long utilized CQ to address a spectrum of diseases and ailments [27]. Its recognized osteogenic properties prompted an exploration into its potential application for periodontitis. Our findings confirm the antibacterial properties of CQ, shedding light on its potential therapeutic role in combating periodontal infections. The efficacy of both samples in preventing the growth of P. gingivalis is of significant clinical relevance, as it suggests their potential utility in the prevention, treatment, and management of periodontal diseases.
The strength of our study lies in its novel focus on the antibacterial activity of CQ against P. gingivalis, a key pathogen in periodontal disease. The demonstrated efficacy of CQ, particularly the ethanolic extract, suggests its potential as an adjunctive therapy for periodontal diseases. Furthermore, incorporating CQ into local drug delivery systems, such as mouth rinses and gels, could enhance its therapeutic application in dental practice.
Despite the promising results, the study is subject to certain limitations. While the extracts effectively targeted P. gingivalis, their efficacy against other periodontal pathogens remains unknown due to the exclusive focus on this single bacterium. Furthermore, the controlled laboratory environment (in vitro) necessitates clinical trials to validate their effectiveness for further clinical applications.
Conclusions
In conclusion, our findings highlight the significant antibacterial properties of CQ aqueous and ethanolic extracts against Porphyromonas gingivalis. The demonstrated efficacy of CQ extracts in inhibiting P. gingivalis opens new avenues for the development of innovative periodontal treatment strategies. To fully harness the potential of CQ extracts, further research is necessary to delve into the underlying mechanisms of their antibacterial action. Understanding these mechanisms will provide valuable insights into how these extracts can effectively combat P. gingivalis .
Acknowledgments
The authors are very grateful to Dr. Kesavaram Padmavathy, Professor, Department of Microbiology, Sree Balaji Dental College and Hospital, Chennai, India, and Prashanth KK, Director, SimBioen Labs and Scientific Private Limited, Chennai, India, for providing the necessary facilities to carry out this study. They would also like to acknowledge the use of ChatGPT (Open AI, Open AI Inc, San Francisco, California, USA) in improving the grammar, punctuation, and overall clarity of the scientific paper.
Disclosures
Human subjects: All authors have confirmed that this study did not involve human participants or tissue.
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Author Contributions
Concept and design: Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S
Acquisition, analysis, or interpretation of data: Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S
Drafting of the manuscript: Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S
Critical review of the manuscript for important intellectual content: Prem Blaisie Rajula, Aathira R. Nair, Ravishankar PL, Sai Sri Soury Geddam, Subhashini B, Lochini S
Supervision: Prem Blaisie Rajula, Ravishankar PL
References
- 1.Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer's disease. Singhrao SK, Harding A, Poole S, Kesavalu L, Crean S. Mediators Inflamm. 2015;2015:137357. doi: 10.1155/2015/137357. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Porphyromonas gingivalis: major periodontopathic pathogen overview. Mysak J, Podzimek S, Sommerova P, et al. J Immunol Res. 2014;2014:476068. doi: 10.1155/2014/476068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.The antimicrobial susceptibility of Porphyromonas gingivalis: genetic repertoire, global phenotype, and review of the literature. Conrads G, Klomp T, Deng D, Wenzler JS, Braun A, Abdelbary MM. Antibiotics (Basel) 2021;10 doi: 10.3390/antibiotics10121438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Dual lifestyle of Porphyromonas gingivalis in biofilm and gingival cells. Sakanaka A, Takeuchi H, Kuboniwa M, Amano A. Microb Pathog. 2016;94:42–47. doi: 10.1016/j.micpath.2015.10.003. [DOI] [PubMed] [Google Scholar]
- 5.The atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes. Belstrøm D, Holmstrup P, Damgaard C, Borch TS, Skjødt MO, Bendtzen K, Nielsen CH. Infect Immun. 2011;79:1559–1565. doi: 10.1128/IAI.01036-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. Jepsen K, Jepsen S. Periodontol 2000. 2016;71:82–112. doi: 10.1111/prd.12121. [DOI] [PubMed] [Google Scholar]
- 7.Antibiotic resistance of subgingival species in chronic periodontitis patients. Ardila CM, Granada MI, Guzmán IC. J Periodontal Res. 2010;45:557–563. doi: 10.1111/j.1600-0765.2010.01274.x. [DOI] [PubMed] [Google Scholar]
- 8.Specific antibiotics in the treatment of periodontitis--a proposed strategy. Beikler T, Prior K, Ehmke B, Flemmig TF. J Periodontol. 2004;75:169–175. doi: 10.1902/jop.2004.75.1.169. [DOI] [PubMed] [Google Scholar]
- 9.Susceptibility of Porphyromonas gingivalis in biofilms to amoxicillin, doxycycline and metronidazole. Larsen T. Oral Microbiol Immunol. 2002;17:267–271. doi: 10.1034/j.1399-302x.2002.170501.x. [DOI] [PubMed] [Google Scholar]
- 10.High resistance against clindamycin, metronidazole and amoxicillin in Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans isolates of periodontal disease. Ardila CM, López MA, Guzmán IC. Med Oral Patol Oral Cir Bucal. 2010;1:947–951. [PubMed] [Google Scholar]
- 11.Antimicrobial resistance in the subgingival microflora in patients with adult periodontitis. A comparison between The Netherlands and Spain. van Winkelhoff AJ, Herrera Gonzales D, Winkel EG, Dellemijn-Kippuw N, Vandenbroucke-Grauls CM, Sanz M. J Clin Periodontol. 2000;27:79–86. doi: 10.1034/j.1600-051x.2000.027002079.x. [DOI] [PubMed] [Google Scholar]
- 12.Antibacterial drug discovery in the resistance era. Brown ED, Wright GD. Nature. 2016;529:336–343. doi: 10.1038/nature17042. [DOI] [PubMed] [Google Scholar]
- 13.Plant natural products targeting bacterial virulence factors. Silva LN, Zimmer KR, Macedo AJ, Trentin DS. Chem Rev. 2016;116:9162–9236. doi: 10.1021/acs.chemrev.6b00184. [DOI] [PubMed] [Google Scholar]
- 14.Ethnobotanical approach versus random approach in the search for new bioactive compounds: support of a hypothesis. Gyllenhaal C, Kadushin MR, Southavong B, et al. Pharm Biol. 2012;50:30–41. doi: 10.3109/13880209.2011.634424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Antibacterial activity of Cissus quadrangularis stem extract on the pathogenic and industrial waste watered bacteria. Mosaib MG, Maruf MAA, Islam R, et al. Eur J Med Health Sci. 2020;2:28–38. [Google Scholar]
- 16.Antibacterial activity of Cissus quadrangularis Linn. Kashikar ND, George I. https://www.ijpsonline.com/abstract/antibacterial-activity-of-cissus-quadrangularis-linn-281.html Indian J Pharm Sci. 2006;68:245–247. [Google Scholar]
- 17.Antioxidant and antimicrobial activity of Cissus quadrangularis L. Chidambara Murthy KN, Vanitha A, Mahadeva Swamy M, Ravishankar GA. https://pubmed.ncbi.nlm.nih.gov/12935320/ J Med Food. 2003;6:99–105. doi: 10.1089/109662003322233495. [DOI] [PubMed] [Google Scholar]
- 18.Bioactive compound analysis and bioactivities of endophytic bacteria from Cissus quadrangularis. Anwar PZ, Sezhian UG, Narasingam A. https://ijpsr.com/bft-article/bioactive-compound-analysis-and-bioactivities-of-endophytic-bacteria-from-cissus-quadrangularis/?view=fulltext Int J Pharm Sci Res. 2020;11:5553–5560. [Google Scholar]
- 19.Analyzing the antihyperglycemic effect of Cissus quadrangularis and Bacopa monnieri on 3T3-L1 cell lines. Katheeja R, Manish S, Ilangovar IGK, Selvaraj J, Vasugi S. https://www.cureus.com/articles/217180-analyzing-the-antihyperglycemic-effect-of-cissus-quadrangularis-and-bacopa-monnieri-on-3t3-l1-cell-lines#!/ Cureus. 2024;16:0. doi: 10.7759/cureus.52661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.A preliminary study on in vitro antioxidant and in vivo anti-inflammatory activity of Cissus quadrangularis Linn. Tiwari M, Gupta PS, Sharma N. https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-45 Res J Pharm Technol. 2021;14:2619–2624. [Google Scholar]
- 21.Evaluation of antidepressant activity of ethanolic extract of Cissus quadrangularis on swiss albino mice. Kapadia S, Kanase V. https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-33 Res J Pharm Technol. 2021;14:4197–4202. [Google Scholar]
- 22.Optimization of extraction conditions of bioactive compounds from Kurdistan species Urtica dioica. Haido MH, Matti AH, Taher SM. https://www.cureus.com/articles/240914-optimization-of-extraction-conditions-of-bioactive-compounds-from-kurdistan-species-urtica-dioica#!/ Cureus. 2024;16:0. doi: 10.7759/cureus.61146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Osteogenic potential of cissus qudrangularis assessed with osteopontin expression. Singh N, Singh V, Singh RK, Pant AB, Pal US, Malkunje LR, Mehta G. https://journals.lww.com/njms/fulltext/2013/04010/osteogenic_potential_of_cissus_qudrangularis.10.aspx. Natl J Maxillofac Surg. 2013;4:52–56. doi: 10.4103/0975-5950.117884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Screening of antibacterial activity of Cissus quadrangularis and Boerhavia diffusa against clinical pathogens. Nandhini K, Tharani J, Sangeetha D. https://www.ijsr.net/getabstract.php Int J Sci Res. 2022;11:668–672. [Google Scholar]
- 25.Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study. Brahmkshatriya HR, Shah KA, Ananthkumar GB, Brahmkshatriya MH. https://journals.lww.com/aayu/fulltext/2015/36020/clinical_evaluation_of_cissus_quadrangularis_as.11.aspx. Ayu. 2015;36:169–173. doi: 10.4103/0974-8520.175542. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: a randomized placebo-controlled trial. Benjawan S, Nimitphong H, Tragulpiankit P, Musigavong O, Prathanturarug S, Pathomwichaiwat T. https://doi.org/10.1016/j.phymed.2022.154115. Phytomedicine. 2022;101:154115. doi: 10.1016/j.phymed.2022.154115. [DOI] [PubMed] [Google Scholar]
- 27.Guidelines for laboratory monitoring of treatment of persistent virus infections. Pillay D, Emery VC, Mutimer D, et al. https://pubmed.ncbi.nlm.nih.gov/12126724/ J Clin Virol. 2002;25:73–92. doi: 10.1016/s1386-6532(02)00018-5. [DOI] [PubMed] [Google Scholar]